Building trust in uncharted territory: Patient considerations for embracing Cell and Gene Therapies

Key Insights

In this presentation, Collins addresses the complexities of building trust and ensuring accessibility for patients considering CGT:

• Patient trust in innovative therapies: While the allure of potentially curative treatments is enticing, many patients face the uncertainty of venturing into uncharted territory. The lack of long-term efficacy data poses challenges, as trust is typically built over time through positive patient experiences and outcomes.
• Building Confidence Through Communication: This presentation discusses the importance of patient testimonials and word-of-mouth endorsements in establishing confidence in new therapies. The need for ongoing post-marketing surveillance is highlighted as a way to enhance trust and ensure safety in the long term.
• Insurance coverage and reimbursement challenges: The presentation delves into the pressing question of whether cell and gene therapies will be adequately covered by insurance. The high costs associated with these innovative treatments and the potential reluctance of payers to cover them as more therapies enter the market is highlighted.
• Value-based arrangements: A key focus is the exploration of new reimbursement models, such as value-based arrangements, which may provide greater flexibility for insurers and ensure that patients have access to potentially curative therapies without prohibitive costs.
• Navigating the hurdles: Collins emphasizes the need for patients and providers to navigate a complex landscape of formularies and other insurance hurdles to ensure access to CGTs. He calls for collaboration among stakeholders to overcome these challenges and streamline access.